Measures activity, not value. Not investment advice.
Shares rose 25% in six months while operating margin was negative, though 12-month net income reached $1B.
GoodInstitutional holders up 5.6% to 413 from 391 last quarter
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
expected around 11 Feb 2027 (an estimate: a year ago it reported on 12 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $656.4M, net income $458.6M.
31 Dec 2021RevenueNet incomeNet losstallest bar $3.4B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$656.4M
$458.6M
30 Jun 2026
$651.0M
$371.4M
31 Mar 2026
$592.1M
-$527.1M
31 Dec 2025
$693.2M
$720.0M
30 Sep 2025
$653.0M
-$341.9M
30 Jun 2025
$651.6M
$317.8M
31 Mar 2025
$585.4M
$64.0M
31 Dec 2024
$667.5M
-$715.8M
30 Sep 2024
$649.7M
$653.2M
30 Jun 2024
$638.5M
-$2.2B
31 Mar 2024
$610.8M
$383.9M
31 Dec 2023
$681.2M
$349.7M
30 Sep 2023
$632.1M
$106.3M
30 Jun 2023
$681.1M
-$1.2B
31 Mar 2023
$676.8M
$69.0M
31 Dec 2022
$730.3M
$827.7M
30 Sep 2022
$680.8M
-$164.2M
30 Jun 2022
$691.1M
-$927.2M
31 Mar 2022
$700.1M
-$3.4B
31 Dec 2021
$732.8M
-$1.6B
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$2.6B
$2.6B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+1.4%
+5.0%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$1.0B
-$675.9M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$37.71
-$24.31
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
51.3%
52.3%
49.6%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-2.4%
8.8%
-7.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
39.5%
-26.4%
-10.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
14.3%
-17.0%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$329.1M
$336.7M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$1.7B
$1.4B
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
$1.2B
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
-$215.9M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.45
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
9.4
33.4
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
3.7
4.1
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
4.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
1.3
2.4
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$1.2M
bought $0, sold $1.2M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+5.6%
413 13F filers vs 391
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
–
No 13F holdings or share count.
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
–
1.2M shares sold short (30 Oct 2026); no share count in the company's filings in our data
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
5.1
1.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+5.4%
1.1M shares sold short in the report before, 1.2M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
85%
85% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 67%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
-11%
34 vs 38 applications
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+0.5%
$656.4M vs $653.0M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-1.6%
$31.2M vs $31.7M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$260K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
8
8 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
4.0×
8 articles in the last 7 days; its usual week has 2.
Price $358.90 on 20 Nov 2026, +18% over 12 months (12-month range $241.71 to $390.34)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $1.4M in the last 12 months (the 12 months before: -$955K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 34 published in the last 12 months, -11% on the 12 months before.Revenue per quarter. Revenue $656.4M in the latest quarter, +0.5% on a year earlier.Capital spending per quarter. Capital spending $31.2M in the latest quarter, -1.6% on a year earlier.Institutional holders (13F filers). 413 13F filers reported holding it in the latest 13F quarter, +11% on a year earlier.Lobbying spend. Lobbying spend: $260K published in the last 12 months, -19% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $732.8M, -7.2% on a year earlier; public on 12 Feb 2022
Quarter ended 31 Mar 2022: $700.1M, -3.7% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $691.1M, -3.5% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $680.8M, -8.9% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Dec 2022: $730.3M, -0.3% on a year earlier; public on 18 Feb 2023
Quarter ended 31 Mar 2023: $676.8M, -3.3% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $681.1M, -1.4% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $632.1M, -7.1% on a year earlier; public on 28 Oct 2023
Quarter ended 31 Dec 2023: $681.2M, -6.7% on a year earlier; public on 17 Feb 2024
Quarter ended 31 Mar 2024: $610.8M, -9.8% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $638.5M, -6.3% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $649.7M, +2.8% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $667.5M, -2.0% on a year earlier; public on 15 Feb 2025
Quarter ended 31 Mar 2025: $585.4M, -4.2% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $651.6M, +2.1% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $653.0M, +0.5% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $693.2M, +3.9% on a year earlier; public on 14 Feb 2026
Quarter ended 31 Mar 2026: $592.1M, +1.1% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $651.0M, -0.1% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $656.4M, +0.5% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $43.2M, +10% on a year earlier; public on 12 Feb 2022
Quarter ended 31 Mar 2022: $28.9M, +48% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $14.3M, -39% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $24.1M, -31% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Mar 2023: $35.7M, +24% on a year earlier; public on 6 May 2023
Quarter ended 31 Mar 2024: $40.2M, +12% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $42.3M; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $40.2M; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $42.9M; public on 15 Feb 2025
Quarter ended 31 Mar 2025: $34.4M, -14% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $45.7M, +8.1% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $31.7M, -21% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $45.8M, +6.7% on a year earlier; public on 14 Feb 2026
Quarter ended 31 Mar 2026: $30.0M, -13% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $32.0M, -30% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $31.2M, -1.6% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 473; public on 14 Feb 2022
31 Mar 2022 report: 474; public on 16 May 2022
30 Jun 2022 report: 464; public on 15 Aug 2022
30 Sep 2022 report: 446; public on 14 Nov 2022
31 Dec 2022 report: 432; public on 14 Feb 2023
31 Mar 2023 report: 468; public on 15 May 2023
30 Jun 2023 report: 428; public on 14 Aug 2023
30 Sep 2023 report: 431; public on 14 Nov 2023
31 Dec 2023 report: 451; public on 14 Feb 2024
31 Mar 2024 report: 446; public on 15 May 2024
30 Jun 2024 report: 411; public on 14 Aug 2024
30 Sep 2024 report: 406; public on 14 Nov 2024
31 Dec 2024 report: 435; public on 14 Feb 2025
31 Mar 2025 report: 406; public on 15 May 2025
30 Jun 2025 report: 363; public on 14 Aug 2025
30 Sep 2025 report: 372; public on 14 Nov 2025
31 Dec 2025 report: 378; public on 17 Feb 2026
31 Mar 2026 report: 385; public on 15 May 2026
30 Jun 2026 report: 391; public on 14 Aug 2026
30 Sep 2026 report: 413; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $80K published
Quarter from 1 Apr 2022: $80K published
Quarter from 1 Jul 2022: $80K published
Quarter from 1 Oct 2022: $80K published
Quarter from 1 Jan 2023: $80K published
Quarter from 1 Apr 2023: $80K published
Quarter from 1 Jul 2023: $80K published
Quarter from 1 Oct 2023: $80K published
Quarter from 1 Jan 2024: $80K published
Quarter from 1 Apr 2024: $80K published
Quarter from 1 Jul 2024: $80K published
Quarter from 1 Oct 2024: $80K published
Quarter from 1 Jan 2025: $80K published
Quarter from 1 Apr 2025: $80K published
Quarter from 1 Jul 2025: $80K published
Quarter from 1 Oct 2025: $80K published
Quarter from 1 Jan 2026: $80K published
Quarter from 1 Apr 2026: $80K published
Quarter from 1 Jul 2026: $100K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $1.2M (12 Nov 2026), 4.4× its normal reading; higher than 91% of its own history.
Short interest spike: had 1.5M shares sold short in the 29 May 2026 report, 1.2× the same report last year Public on 10 Jun 2026.
Reported lobbying spend: $20K in Q3 2026, $80K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
27 Jul 2026
Ended
Forbes-Tatefor Bio-Rad Laboratories
Issues related to advanced diagnostic testing and laboratory tools.; Issues related to biomedical research and development; Issues related to pathogen surveillance.Medicare/Medicaid, Health issues, Defense
had 1.5M shares sold short in the 29 May 2026 report, 1.2× the same report last year.
Same report last year: 1.2M; its normal report is 949K.
See the evidence
This period
1.5M (the 29 May 2026 report)
Normal report (median of 24 earlier)
949K
Typical spread (median absolute deviation)
70K
How far from its usual level
+5.4
Same report last year
1.2M
History used
3,073 days
the 29 May 2026 report24 earlier reportsnormal: 949K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 15 May 2026 report, 1.0× the same report last year.
Same report last year: 1.3M; its normal report is 949K.
See the evidence
This period
1.3M (the 15 May 2026 report)
Normal report (median of 24 earlier)
949K
Typical spread (median absolute deviation)
70K
How far from its usual level
+3.8
Same report last year
1.3M
History used
3,059 days
the 15 May 2026 report24 earlier reportsnormal: 949K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 13 Sep 2024 report, 3.5× the same report last year.
Same report last year: 388K; its normal report is 583K.
See the evidence
This period
1.3M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
583K
Typical spread (median absolute deviation)
140K
How far from its usual level
+3.7
Same report last year
388K
History used
2,450 days
the 13 Sep 2024 report24 earlier reportsnormal: 583K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 31 Jul 2024 report, 3.8× the same report last year.
Same report last year: 336K; its normal report is 546K.
See the evidence
This period
1.3M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
546K
Typical spread (median absolute deviation)
119K
How far from its usual level
+4.1
Same report last year
336K
History used
2,406 days
the 31 Jul 2024 report24 earlier reportsnormal: 546K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.4M shares sold short in the 15 Jul 2024 report, 4.3× the same report last year.
Same report last year: 333K; its normal report is 524K.
See the evidence
This period
1.4M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
524K
Typical spread (median absolute deviation)
120K
How far from its usual level
+5.0
Same report last year
333K
History used
2,390 days
the 15 Jul 2024 report24 earlier reportsnormal: 524K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 28 Jun 2024 report, 4.5× the same report last year.
Same report last year: 283K; its normal report is 512K.
See the evidence
This period
1.3M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
512K
Typical spread (median absolute deviation)
113K
How far from its usual level
+4.6
Same report last year
283K
History used
2,373 days
the 28 Jun 2024 report24 earlier reportsnormal: 512K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 649K shares sold short in the 30 Nov 2023 report, 3.3× the same report last year.
Same report last year: 198K; its normal report is 287K.
See the evidence
This period
649K (the 30 Nov 2023 report)
Normal report (median of 24 earlier)
287K
Typical spread (median absolute deviation)
47K
How far from its usual level
+5.2
Same report last year
198K
History used
2,162 days
the 30 Nov 2023 report24 earlier reportsnormal: 287K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 572K shares sold short in the 15 Nov 2023 report, 2.0× the same report last year.
Same report last year: 284K; its normal report is 284K.
See the evidence
This period
572K (the 15 Nov 2023 report)
Normal report (median of 24 earlier)
284K
Typical spread (median absolute deviation)
48K
How far from its usual level
+4.1
Same report last year
284K
History used
2,147 days
the 15 Nov 2023 report24 earlier reportsnormal: 284K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $34.6M on capital projects in the quarter ended 30 Sep 2021, 1.7× the same quarter last year.
Same quarter last year: $20.0M; its normal quarter is $21.6M.
See the evidence
This period
$34.6M (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$21.6M
Typical spread (median absolute deviation)
$1.9M
How far from its usual level
+4.6
Same quarter last year
$20.0M
History used
3,745 days
the quarter ended 30 Sep 20218 earlier quartersnormal: $21.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
reported revenue of $789.8M for the quarter ended 31 Dec 2020, 1.3× the same quarter last year.
Same quarter last year: $624.5M; its normal quarter is $572.1M.
See the evidence
This period
$789.8M (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
$572.1M
Typical spread (median absolute deviation)
$26.7M
How far from its usual level
+3.8
Same quarter last year
$624.5M
History used
4,202 days
the quarter ended 31 Dec 20208 earlier quartersnormal: $572.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
spent $39.2M on capital projects in the quarter ended 31 Dec 2020, 1.8× the same quarter last year.
Same quarter last year: $21.6M; its normal quarter is $21.9M.
See the evidence
This period
$39.2M (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
$21.9M
Typical spread (median absolute deviation)
$1.8M
How far from its usual level
+6.4
Same quarter last year
$21.6M
History used
3,472 days
the quarter ended 31 Dec 20208 earlier quartersnormal: $21.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Showing the newest 40 of 59 entries; narrow the window or the kind of data to see older ones.
Not listed: 191 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000012208
Ticker
BIO
Domain
bio-rad.com
Employer name
Bio-Rad Laboratories, Inc. (1 unverified)
Hq location
CA|HERCULES|94547 (1 unverified)
Lobbying client
bio rad laboratories
Name
Bio-Metrics (U.K.) Limited, Bio-Rad, Bio-Rad 1, Bio-Rad AbD Serotec GmbH and 47 more
Wikidata
Q2904022
Wikipedia
Bio-Rad Laboratories
DOL H-1B labor condition applications and PERM certifications928 data points14 Oct 2019 to 28 Sep 2026
Federal lobbying disclosures (LDA)2 records, 78 data points23 May 2020 to 30 Sep 2026
SEC Form 13F institutional holdings1 record, 481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)137 records25 Feb 2016 to 4 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1217 data points31 Dec 2007 to 30 Sep 2026
SEC Form 4 insider transactions85 records, 268 data points14 Mar 2016 to 12 Nov 2026
FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026